vitro pd model sh sy5y human neuroblastoma cells  (ATCC)

Journal: Oncology Reports

Article Title: Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model

doi: 10.3892/or.2016.4902

Figure Lengend Snippet: Bevacizumab shows antitumor activity in the early phase but not in the late phase in HT-29 xenograft model. Mice were randomized into 2 groups (n=5–10/group). Bevacizumab and control human IgG were intraperitoneally administered once a week. Data points show mean ± SD of tumor volume. Control, open circles; bevacizumab, closed circles. a P<0.05 versus control IgG group by Wilcoxon test.

Article Snippet: HT-29 tumor tissues collected on day 50 from the bevacizumab PD model were homogenized with cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) and phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan).

Techniques: Activity Assay, Control

Journal: Oncology Reports

Article Title: Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model

doi: 10.3892/or.2016.4902

Figure Lengend Snippet: Combination therapy with bevacizumab plus capecitabine inhibits tumor growth and tumor angiogenesis in the HT-29 xenograft bevacizumab PD model. Antitumor activity (A) and anti-angiogenic activity (B) of combination therapy with capecitabine plus bevacizumab in the HT-29 xenograft model unresponsive to bevacizumab. Mice that had been treated with bevacizumab on days 1 and 8 were randomly allocated to control, bevacizumab, capecitabine, and bevacizumab plus capecitabine groups on day 29 (n=7/group). CD31 immunostaining in tumor tissue at day 50 (n=7/group). Data points show mean ± SD of tumor volume. Control, open circles; bevacizumab, closed circles; capecitabine, cross marks; combination group, closed triangles. The box-and-whisker plots show mean ± SD. a P<0.05 versus control group; b P<0.05 versus capecitabine group; c P<0.05 versus bevacizumab group by Wilcoxon test.

Article Snippet: HT-29 tumor tissues collected on day 50 from the bevacizumab PD model were homogenized with cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) and phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan).

Techniques: Activity Assay, Control, Immunostaining, Whisker Assay

Journal: Oncology Reports

Article Title: Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model

doi: 10.3892/or.2016.4902

Figure Lengend Snippet: Combination therapy did not change the expression of stromal cell-derived angiogenic factors in tumor tissues. Changes in stromal cell-derived angiogenic factors. Membranes-based antibody arrays were reacted with homogenized tumor tissue harvested from the control, bevacizumab, capecitabine, and combination group on day 50.

Article Snippet: HT-29 tumor tissues collected on day 50 from the bevacizumab PD model were homogenized with cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) and phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan).

Techniques: Expressing, Derivative Assay, Control

Journal: Oncology Reports

Article Title: Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model

doi: 10.3892/or.2016.4902

Figure Lengend Snippet: Combination therapy suppresses tumor cell-derived VEGF and galectin-3 in tumor tissues. (A) Membranes-based antibody arrays were reacted with tumor tissue homogenates from the control group, bevacizumab group, capecitabine group, and combination group on day 50. (B) Levels of free VEGF in the tumor tissues (n=7). (C) Levels of galectin-1 and galectin-3 in the tumor tissues (n=7). The control group (open), bevacizumab group (horizontal striped), capecitabine group (hatched), and combination group (closed). Columns show mean ± SD. a P<0.05 versus control by Wilcoxon test. (D) Downregulation of galectin-3 expression by 5-FU in in vitro culture. Culture supernatant was collected and subjected to ELISA (n=3). Columns show mean ± SD. a P<0.05 versus control by Dunnett's test.

Article Snippet: HT-29 tumor tissues collected on day 50 from the bevacizumab PD model were homogenized with cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA) with protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA) and phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan).

Techniques: Derivative Assay, Control, Expressing, In Vitro, Enzyme-linked Immunosorbent Assay